Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Imprimis plans to offer $100 EpiPen

Imprimis CEO Mark Baum discusses company's plans for a $100 EpiPen compound alternative.